Moderna (NASDAQ:MRNA) Insider Shannon Thyme Klinger Sells 3,471 Shares

Posted by Brian Himes on Sep 4th, 2026

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Stock Performance

MRNA opened at $148.87 on Friday. The firm has a market capitalization of $59.43 billion, a P/E ratio of -18.63 and a beta of 1.10. The stock’s 50 day moving average price is $84.18 and its two-hundred day moving average price is $62.87. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the company earned ($2.13) earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -6.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Moderna in the 2nd quarter worth approximately $2,142,877,000. California State Teachers Retirement System boosted its stake in Moderna by 6,698.1% in the 2nd quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company’s stock valued at $1,938,523,000 after buying an additional 27,274,128 shares in the last quarter. Capital World Investors acquired a new stake in Moderna in the 4th quarter valued at $378,299,000. Invesco Ltd. boosted its stake in Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after buying an additional 1,115,131 shares in the last quarter. Finally, Theleme Partners LLP bought a new stake in Moderna in the second quarter valued at $564,272,000. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the subject of several research analyst reports. Rothschild & Co Redburn cut shares of Moderna from a “neutral” rating to a “sell” rating and upped their target price for the company from $40.00 to $81.00 in a research note on Thursday. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a research report on Friday, August 28th. They issued a “hold” rating on the stock. Citigroup boosted their price objective on shares of Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Bradesco Corretora raised shares of Moderna to an “outperform” rating in a research report on Friday, August 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $76.72.

Get Our Latest Research Report on Moderna

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Moderna’s Phase 3 INTerpath-001 trial of intismeran autogene with Merck’s Keytruda met its primary recurrence-free-survival endpoint in resected stage IIB–IV melanoma. The result represents the first positive Phase 3 outcome for an mRNA-based cancer therapy and materially strengthens Moderna’s oncology outlook, although detailed data have not yet been released. Moderna cancer vaccine article
Positive Sentiment: Technical analysts see a bullish pennant forming after the breakout, potentially signaling another advance if the stock clears nearby resistance. Elevated short interest could amplify gains through additional short covering. Moderna bullish pennant forecast
Positive Sentiment: The FDA approved Moderna’s mFlusiva mRNA flu vaccine for adults, adding a commercial product to the company’s portfolio. Brookline Capital Markets also modestly improved its 2026–2028 EPS forecasts and retained a Buy rating, projecting a return to positive EPS in 2028. FDA approves Moderna flu vaccine
Neutral Sentiment: Chief legal officer Shannon Klinger sold 3,471 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. Because the sale was planned and tax-related, it offers limited information about management’s view of the stock.
Negative Sentiment: Rothschild & Co. downgraded Moderna from Neutral to Sell, arguing that the cancer-vaccine rally has left the shares overvalued. Its $81 price target is substantially below the recent trading level, even after being raised from $40. Rothschild Moderna sell rating
Negative Sentiment: GSK is advancing its own mRNA influenza vaccine into Phase 3 after reporting stronger immune responses in Phase 2. That program could challenge mFlusiva and increase competition in Moderna’s newer commercial market. GSK mRNA flu vaccine development

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.